An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the ...

Scientists are testing and working on the world’s first acne vaccine, hoping to offer a long-term alternative to current ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to ...

COPD represents a significant opportunity for Sanofi and its U.S. drug partner Regeneron as Dupixent is the first biologic approved for the condition, which is the fourth-leading cause of death in ...

Sanofi SAN0.13%increase; green up pointing triangle posted better-than-expected sales and profit in the first quarter on higher demand for its key drugs and vaccines. The French pharmaceutical ...